Anti-CD3 antibodies for type 1 diabetes: Beyond expectations

The Lancet

Volumn 378, Issue 9790, 2011, Pages 459-460

  Bach, Jean François ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; HEMOGLOBIN A1C; INSULIN; OTELIXIZUMAB; PLACEBO; TEPLIZUMAB;

HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 80051473845     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60980-X     Document Type: Note

References (12)

1. G Feutren, L Papoz, R Assan et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial Lancet 328 1986 119 124
2. Diabetes Prevention Trial - Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus N Engl J Med 346 2002 1685 1691
3. M Walter, A Philotheou, F Bonnici, AG Ziegler, R Jimenez for the NBI-6024 Study Group No effect of the altered-peptide ligand NBI-6024 on beta cell residual function and insulin needs in new-onset type 1 diabetes Diabetes Care 32 2009 2036 2040
4. J Ludvigsson, M Faresjo, M Hjorth et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 2008 1909 1920
5. I Raz, D Elias, A Avron, M Tamir, M Metzger, IR Cohen β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial Lancet 358 2001 1749 1753 (Pubitemid 33152998)
6. L Chatenoud, JA Bluestone CD3-specific antibodies: a portal to the treatment of autoimmunity Nat Rev Immunol 7 2007 622 632 (Pubitemid 47123550)
7. L Chatenoud, E Thervet, J Primo, JF Bach Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Proc Natl Acad Sci USA 91 1994 123 127 (Pubitemid 24018655)
8. KC Herold, W Hagopian, JA Auger et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692 1698 (Pubitemid 34547482)
9. B Keymeulen, E Vandemeulebroucke, AG Ziegler et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 352 2005 2598 2608 (Pubitemid 41007846)
10. B Keymeulen, M Walter, C Mathieu et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 53 2010 614 623
11. N Sherry, W Hagopian, J Ludvigsson for the Protégé Trial Investigators Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised placebo-controlled trial Lancet 2011 10.1016/S0140-6736(11)60931-8 published online June 28.
12. GlaxoSmithKline GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-10039.htm March 11, 2011 (accessed June 9, 2011).